Spartalizumab
Aliases
PDR001, PDR-001
6 clinical trials
3 products
1 abstract
44 indications
Indication
Pancreatic CancerIndication
Stage IIIC Cutaneous Melanoma AJCC v8Indication
Stage IIID Cutaneous Melanoma AJCC v8Indication
Thyroid CancerIndication
FollicularIndication
Papillary Thyroid CancerIndication
Follicular Thyroid CancerIndication
Hürthle cell tumorIndication
Thyroid CarcinomaIndication
Hürthle Cell Thyroid NeoplasiaIndication
MSI-H Colorectal CancerIndication
MelanomaIndication
Anal CancerIndication
MesotheliomaIndication
Triple-Negative Breast CancerIndication
Adenocarcinoma of the LungIndication
CholangiocarcinomaIndication
Cervical CancerIndication
Renal Cell CarcinomaIndication
Stomach AdenocarcinomaIndication
Esophageal adenocarcinomaIndication
Uterine AdenocarcinomaIndication
Head and Neck Squamous Cell CarcinomaIndication
SarcomaIndication
squamous cell carcinoma of the lungIndication
Bladder CancerIndication
Hepatocellular CarcinomaIndication
Uveal melanomaIndication
Breast Cancer (HER2-positive)Indication
Pancreatic adenocarcinomaIndication
Esophageal Squamous Cell CarcinomaIndication
Ovarian CancerIndication
Uterine CarcinosarcomaIndication
Small Cell Lung CancerIndication
Colorectal AdenocarcinomaIndication
Prostate CancerIndication
Carcinoma of Unknown PrimaryIndication
HistologyIndication
cancerIndication
Renal CellIndication
Pancreatic Ductal AdenocarcinomaIndication
NSCLCAbstract
Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis.Org: Niterói, Acre Federal University, Federal University of Santa Catarina, Florianopolis, Viçosa Federal University,
Clinical trial
A Phase Ib/II Trial of Siltuximab and Spartalizumab in Metastatic Pancreatic CancerStatus: Completed, Estimated PCD: 2023-04-05
Clinical trial
Altering Adjuvant Therapy Based on Pathologic Response to Neoadjuvant Dabrafenib and Trametinib (ALTER-PATH NeoDT)Status: Completed, Estimated PCD: 2023-10-09
Clinical trial
Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid CancerStatus: Active (not recruiting), Estimated PCD: 2025-09-02
Clinical trial
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified CutoffStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)Status: Terminated, Estimated PCD: 2024-04-26
Product
trametinib + PDR001